ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma

The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
TTUHSC Amarillo Awarded $50,000 Grant for Cutting-Edge Cancer Research
TTUHSC in Amarillo has received a $50,000 grant from the Harrington Cancer and Health Foundation to support groundbreaking cancer research led by Hiranmoy Das, Ph.D.
TTUHSC Researchers to Study Gene’s Role in Prostate Cancer Metastasis
With support from a three-year, $1.85 million grant, Srinivas Nandana, Ph.D., and co-investigator Manisha Tripathi, Ph.D., from the Department of Cell Biology and Biochemistry at the TTUHSC School of Medicine will investigate the role of TBX2.
TTUHSC Researcher Receives National Award
The AACR presented its Minority-Serving Institution Faculty Scholar in Cancer Research Award to TTUHSC Associate Professor Duke Appiah, Ph.D., MPH, at the AACR 2025 Annual Meeting in Chicago recently.
Recent Stories
Texas Tech University Health Sciences Center Earns SACSCOC Recognition
TTUHSC has received a clean bill of health from the regional accrediting body, the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), following a Fifth-Year Interim Review by a committee from peer institutions.
Noise-Induced Hearing Loss in Rural Adolescents
Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.
TTUHSC Amarillo Awarded $50,000 Grant for Cutting-Edge Cancer Research
TTUHSC in Amarillo has received a $50,000 grant from the Harrington Cancer and Health Foundation to support groundbreaking cancer research led by Hiranmoy Das, Ph.D.